West Pharmaceutical Engagements Showcase Commitment to Investors and Healthcare Innovation

### West Pharmaceutical Services Focuses on Investor Engagement and Industry Leadership

West Pharmaceutical Services, Inc., a key player in the injectable drug administration sector, emphasizes its dedication to investor transparency through its scheduled participation in two prominent healthcare conferences. The company is set to engage an audience at the Barclays Global Healthcare Conference on March 10, 2026, with a fireside chat at 9:00 AM EDT, followed by the KBCM Healthcare Forum on March 18, 2026, at 1:30 PM EDT. These events represent opportunities for West to showcase its innovative solutions and establish connections within the investment community. Stakeholders can tune in to live webcasts of both discussions on the Investors section of West's official website, with recordings available for approximately 90 days after each event.

Established in Exton, Pennsylvania, West Pharmaceutical Services has built a robust network, employing over 10,000 individuals across 50 locations, including 25 advanced manufacturing facilities worldwide. This extensive infrastructure supports the company’s mission to provide safe and effective containment and delivery of life-saving medicines. In fiscal year 2025, the company recorded substantial net sales of $3.07 billion, reflecting its strong market position and operational capacity. As a member of the Standard & Poor's 500 index, West’s continued growth and commitment to innovation reinforces its status as a trusted partner for both established and emerging drug developers.

West Pharmaceutical Services manufactures and delivers over 41 billion components and devices each year, underscoring its crucial role in the healthcare solutions industry. This commitment to high-quality production not only addresses the increasing demand for injectable drug delivery systems but also elevates the standard of care available to patients worldwide. By prioritizing interaction with investors and industry stakeholders through these conferences, West Pharmaceutical positions itself as a leader in healthcare innovation and responsiveness to market dynamics.

In addition to its focus on investor relations, West Pharmaceutical aims to continuously enhance its product offerings. By staying attuned to the needs of drug developers and the evolving healthcare landscape, the company seeks to implement cutting-edge solutions that align with industry advancements.

Overall, West Pharmaceutical's recent initiatives highlight a dual commitment: fostering investor relationships while leading in the development of essential drug delivery technologies that support global health advancements. For further details, stakeholders are encouraged to visit West’s comprehensive website at www.westpharma.com.